Skip to content
10-K

Annual Report

Panbela Therapeutics, Inc.

0001437749-24-009418

← back to feed
Filed
Mar 26, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 22, 2024 4.85M sh
Operating Cash Flow FY 2023 · Dec 31, 2023 −$25.25M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$15.28M
Long Term Debt FY 2023 · Dec 31, 2023 $4.19M
Long Term Debt FY 2023 · Dec 31, 2022 $5.19M
Cash And Equivalents FY 2023 · Dec 31, 2023 $2.58M
Cash And Equivalents FY 2023 · Dec 31, 2022 $1.29M
Stockholders Equity FY 2023 · Dec 31, 2023 −$4.71M
Stockholders Equity FY 2023 · Dec 31, 2022 −$8.05M
Current Liabilities FY 2023 · Dec 31, 2023 $12.32M
Current Liabilities FY 2023 · Dec 31, 2022 $7.83M
Total Liabilities FY 2023 · Dec 31, 2023 $16.51M
Total Liabilities FY 2023 · Dec 31, 2022 $13.03M
Current Assets FY 2023 · Dec 31, 2023 $3.06M
Current Assets FY 2023 · Dec 31, 2022 $1.78M
Total Assets FY 2023 · Dec 31, 2023 $11.8M
Total Assets FY 2023 · Dec 31, 2022 $4.98M
Eps Basic FY 2023 · Dec 31, 2023 −$316.52
Eps Basic restated FY 2023 · Dec 31, 2022 −$41,341.21
Sga Expense FY 2023 · Dec 31, 2023 $5.03M
Sga Expense FY 2023 · Dec 31, 2022 $6.04M
Rd Expense FY 2023 · Dec 31, 2023 $20.61M
Rd Expense FY 2023 · Dec 31, 2022 $28.05M
Net Income FY 2023 · Dec 31, 2023 −$25.26M
Net Income FY 2023 · Dec 31, 2022 −$34.93M
Operating Income FY 2023 · Dec 31, 2023 −$25.65M
Operating Income FY 2023 · Dec 31, 2022 −$34.09M